



Australian Government

Department of Health
Therapeutic Goods Administration

Advisory Committee on Medicines

Meeting Statement

Out of Session Meeting, Thursday 13 January 2022

Section A: Pre-market registration applications referred for advice

At this meeting, the committee's advice was sought on 2 applications under evaluation by the TGA. The applications included:

Active ingredient (TRADENAME)	Sponsor	Therapeutic area
Type A (new chemical entity)		
PF07321332 / ritonavir (PAXLOVID)	Pfizer Australia Pty Ltd	For treatment of COVID-19

Further details of the ACM discussion and advice associated with these items may be released within the Australian Public Assessment Reports (AusPARs). Please note that there is a delay from when an application was considered at ACM and the publication of the AusPAR. To browse all AusPARs see: <<https://www.tga.gov.au/browse-auspars-active-ingredient>>

Further information

For further information on the Advisory Committee on Medicines, please visit: <https://www.tga.gov.au/committee/advisory-committee-medicines-acm> or contact the ACM Secretary by email: ACM@health.gov.au.